Oregon Passes Bill to Support Medical Cannabis Among Hospice Patients

Why It Matters

The law expands access to cannabis as a therapeutic alternative in end‑of‑life care, potentially lowering opioid use and setting a precedent for other states grappling with hospice pain management.

Key Takeaways

• Ryan’s Law requires hospice providers to allow medical cannabis
• Adds hospice care as a qualifying condition for Oregon medical marijuana
• Facilities must create policies and train staff for safe cannabis administration
• Only one caregiver designation existed in 2025, serving eight patients

Pulse Analysis

Oregon’s new Ryan’s Law reflects a growing national conversation about integrating medical cannabis into hospice and palliative care. As the opioid crisis continues to drive policymakers to seek safer pain‑management alternatives, states are looking to cannabis for its analgesic and anxiolytic properties. By formally recognizing hospice and end‑of‑life care as a qualifying condition, Oregon joins a handful of jurisdictions that are redefining eligibility criteria for medical marijuana, signaling a shift toward patient‑centered, non‑opioid therapies.

The legislation imposes concrete operational requirements on facilities: they must draft clear cannabis‑use policies, train staff on dosing and safety, and designate a responsible individual to attest to caregiver responsibilities. This addresses the low uptake observed after the 2025 caregiver‑attestation law, which saw only one organization serving eight patients. By tightening the administrative framework and providing clearer guidance, Ryan’s Law aims to remove the procedural barriers that previously discouraged facilities from participating.

For the broader healthcare and cannabis industries, Oregon’s move could serve as a template. If successful, it may encourage other states to adopt similar statutes, expanding market opportunities for medical‑cannabis providers while also prompting hospice operators to invest in staff education and compliance systems. Ultimately, the law promises to improve quality of life for terminal patients by offering a less sedating alternative to opioids, while also generating data that could inform future regulatory decisions nationwide.